510(k) · Radiology

CaRi-Plaque

by Caristo Diagnostics Ltd.

CaRi-Plaque is an AI-enabled medical device from Caristo Diagnostics Ltd. that the U.S. FDA cleared through 510(k) K242240 on February 20, 2025. Its lead review panel is Radiology and its primary product code is LLZ (System, Image Processing, Radiological).

See also FDA-cleared AI radiology devices in 2025, all FDA AI clearances in 2025, top radiology AI devices.

Key facts

Submission numberK242240
Pathway510(k)
Date of final decision
Company (FDA list)Caristo Diagnostics Ltd.
Lead review panelRadiology
Primary product codeLLZ — System, Image Processing, Radiological
Applicant (openFDA)Caristo Diagnostics , Ltd.
Applicant locationOxford, GB
Device classClass 2
Regulation number21 CFR 892.2050
Decision codeSESE
Submission typeTraditional

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. CaRi-Plaque went through this pathway (K242240).

openFDA lists it as a Class 2 device under 21 CFR 892.2050. Class II devices are moderate risk and are subject to general and special controls.

Product code LLZ covers 161 devices on the FDA AI list. By decision date, this device is #152 of 161 under that code. Caristo Diagnostics Ltd. has 1 AI-enabled device on the list, and the Radiology panel accounts for 1,230 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code LLZ)